Diversified Trust Co. Has $1.40 Million Position in Incyte Corporation $INCY

Diversified Trust Co. cut its stake in Incyte Corporation (NASDAQ:INCY) by 37.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 14,135 shares of the biopharmaceutical company’s stock after selling 8,360 shares during the quarter. Diversified Trust Co.’s holdings in Incyte were worth $1,396,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Harbor Capital Advisors Inc. acquired a new stake in Incyte during the third quarter valued at $26,000. Root Financial Partners LLC purchased a new position in Incyte in the third quarter valued at about $28,000. Quent Capital LLC acquired a new position in Incyte in the 3rd quarter worth about $30,000. MUFG Securities EMEA plc acquired a new position in Incyte in the 2nd quarter worth about $32,000. Finally, CYBER HORNET ETFs LLC purchased a new stake in shares of Incyte during the 2nd quarter worth about $33,000. 96.97% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on INCY shares. Stifel Nicolaus lifted their price target on Incyte from $119.00 to $120.00 and gave the company a “buy” rating in a report on Wednesday, February 11th. Jefferies Financial Group downgraded Incyte from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $120.00 to $94.00 in a report on Monday, March 16th. HC Wainwright reaffirmed a “buy” rating and set a $135.00 price objective on shares of Incyte in a research report on Wednesday. UBS Group reduced their target price on shares of Incyte from $104.00 to $94.00 and set a “neutral” rating for the company in a research note on Wednesday. Finally, Weiss Ratings downgraded shares of Incyte from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, March 17th. Nine research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $104.89.

Insider Buying and Selling

In other news, insider Pablo J. Cagnoni sold 18,667 shares of Incyte stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $94.24, for a total value of $1,759,178.08. Following the transaction, the insider owned 234,800 shares of the company’s stock, valued at $22,127,552. This trade represents a 7.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Mohamed Khairie Issa sold 10,856 shares of the business’s stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $109.07, for a total transaction of $1,184,063.92. Following the completion of the sale, the executive vice president owned 66,132 shares of the company’s stock, valued at $7,213,017.24. The trade was a 14.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 17.80% of the stock is owned by corporate insiders.

Incyte Price Performance

Shares of NASDAQ:INCY opened at $92.23 on Thursday. The stock has a market capitalization of $18.35 billion, a P/E ratio of 14.39, a P/E/G ratio of 0.72 and a beta of 0.84. The business has a 50-day moving average of $99.56 and a two-hundred day moving average of $96.94. Incyte Corporation has a fifty-two week low of $53.56 and a fifty-two week high of $112.29. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.32 and a quick ratio of 3.25.

Incyte (NASDAQ:INCY) last issued its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.80 EPS for the quarter, missing analysts’ consensus estimates of $1.96 by ($0.16). Incyte had a net margin of 25.03% and a return on equity of 26.34%. The company had revenue of $1.51 billion for the quarter, compared to analyst estimates of $1.35 billion. During the same period in the prior year, the company posted $1.43 EPS. The business’s revenue was up 27.8% on a year-over-year basis. On average, equities research analysts predict that Incyte Corporation will post 4.86 EPS for the current fiscal year.

Trending Headlines about Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: HC Wainwright reaffirmed a “buy” rating and lifted its price target to $135, signalling strong analyst conviction and providing notable upside potential relative to the current share level. Article Title
• Neutral Sentiment: Incyte announced executive leadership appointments — a corporate governance update that may be viewed positively if it strengthens execution but is unlikely to move fundamentals immediately. Incyte Announces Executive Leadership Appointments
• Neutral Sentiment: Coverage piece assessing Incyte’s valuation after mixed short-term returns and strong one‑year performance — useful context for investors but not a direct near-term catalyst. A Look At Incyte (INCY) Valuation
• Neutral Sentiment: Multiple reports flagged a “significant” rise in short interest for March, but published figures show zero shares and NaN changes — likely a data/reporting anomaly. Investors should treat the short-interest headlines cautiously and monitor clearer data from exchanges.
• Negative Sentiment: UBS cut its price target from $104 to $94 and moved to a “neutral” rating, which narrows perceived upside and can weigh on sentiment among more conservative investors. Article Title
• Neutral Sentiment: A sector competitor (Karyopharm) reported mixed Phase 3 trial data in myelofibrosis — a development that may shift sector sentiment or competitive positioning but has uncertain direct impact on Incyte’s pipeline. Karyopharm myeloma drug yields mixed data in myelofibrosis trial

Incyte Profile

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.